Clinical trials: SARS-CoV-2 Infection
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
SARS-CoV-2
Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
- Trial name
- NCT04715997
- Testing
- GX-19N
- Where
- 5 sites in South Korea
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
COVID-19
TCM Differentiation and Treatment Protocol of COVID-19
Evaluation of the efficacy and safety of TCM differential treatment of COVID-19 in Jiangsu Province based on the historical prospective multicenter cohort study.
- Trial name
- TDATPOC (NCT04306497)
- Testing
- TCM prescriptions
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
COVID-19 Infection
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration.
- Trial name
- UMSC01 (NCT05501418)
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Controlled normal saline
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05112913
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Covid19
Bucillamine in Treatment of Patients With COVID-19
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19.
- Trial name
- NCT04504734
- Testing
- Bucillamine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 713 people
- Sponsor
- Revive Therapeutics, Ltd.
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
Covid19
Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients
SARS-CoV-2 infection is a condition characterized by excessive leukocyte infiltration, massive release of chemokines, proteases and cytokines, the so-called "cytokine storm", which promote the inflammatory process and contribute…
- Trial name
- NCT04568876
- Testing
- Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension, Standard Therapy
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Epitech Group SpA
COVID-19 Respiratory Infection
Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose
A total sample size of 875 healthy volunteers ages ≥18 years will be recruited in this study in the ratio of 2:1:2:1:1. Group 1: (BBV154 in COVAXIN recipients): In this group, 250 participants will be recruited and administered…
- Trial name
- NCT05567471
- Testing
- BBV154 Intranasal Vaccine, Intramuscular vaccine COVAXIN, Covishield
- Where
- 9 sites in India
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04623021
- Testing
- Nafamostat Mesilate
- Where
- 11 sites in Russia
- Volunteers
- 104 people
- Sponsor
- Chong Kun Dang Pharmaceutical
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against…
- Trial name
- NCT04588480
- Testing
- BNT162b2
- Where
- 2 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, Vaccines
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
The safety and immunogenicity of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
- Trial name
- NCT05576623
- Testing
- AdCLD-CoV19-1 OMI (Part A), AdCLD-CoV19-1 OMI (Part B)
- Where
- 7 sites in South Korea
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
Corona Virus Infection, Covid19
Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
A preparation of CimertrA, comprising Artemisinin, Curcumin, and Boswellia, and Vitamin C in a nanoparticular formulation, is proposed as a treatment for the disease associated with the novel coronavirus SARS-CoV-2.
- Conditions
- Corona Virus Infection, Covid19, SARS-CoV Infection
- Trial name
- CimetrA (NCT04802382)
- Testing
- Confirm SARS-CoV-2 infection, Physical Examination, Vital Signs
- Where
- 2 sites in Israel
- Volunteers
- 252 people
- Sponsor
- MGC Pharmaceuticals d.o.o
Influenza, Human, COVID-19
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season.
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B
- Trial name
- WAVE (NCT06207929)
- Where
- United States
- Volunteers
- 18,157 people, healthy volunteers welcome
- Sponsor
- Evidation Health
COVID-19
Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated…
- Trial name
- NCT05433272
- Testing
- Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Colombia
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech (Colombia) S.A.S.
COVID-19
A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing
The negative global consequences of the COVID-19 pandemic has prompted efforts to develop efficient laboratory testing protocols that can be quickly scaled in a practical way.
- Trial name
- NCT04537572
- Testing
- comparison of sample collection methods
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salveo Diagnostics
Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19).
- Trial name
- NCT05675072
- Testing
- FB2001
- Where
- China
- Volunteers
- 1,336 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
- Trial name
- NCT07089706
- Testing
- mRNA-1283.251 Variant-containing Formulation
- Where
- 5 sites in United States
- Volunteers
- 832 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.